TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04374760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-intervention
Description: SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS-intervention
Description: SMS-intervention consisting of a series of text messages, grounded in behavioral change theory, aimed at generating intention and autonomous motivation to get screened.
Study: NCT00805272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QTF-TB Gold and T-SPOT TB
Description: evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
Study: NCT02787187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy with Standard lymphadenectomy
Description: Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with Extended lymphadenectomy
Description: Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
Study: NCT02559297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
Study: NCT04360980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine Tablets
Description: 1.5 mg loading then 0.5 mg BID P.O
Study: NCT02282150

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrocortisone
Description: Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Plenadren
Description: 10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
Study: NCT01710995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zegerid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zegerid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losec
Study: NCT00123292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
Study: NCT01475175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRT pacing at rest and during exercise
Description: CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
Study: NCT02836028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Talazoparib monotherapy 1mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Talazoparib
Description: Talazoparib monotherapy 1mg/day orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: temozolomide 37.5 mg/m2 on days 1-5 of each cycle
Study: NCT04090710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab/ Nivolumab
Description: induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT + Ipilimumab/Nivolumab
Description: SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
Study: NCT02361541

Intervention type: PROCEDURE
Intervention: HCV screening
Description: HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
Study: NCT01289236

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milnacipran
Description: 1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milnacipran
Description: 1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
Study: NCT04651621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation over the SMA
Description: Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation over the SMA
Description: Each cTBS session consists of bursts of three pulses delivered with a rate of 50 Hz, with bursts repeated at a rate of 5 Hz for a total duration of 40 seconds, summing up to 600 pulses, 100% of motor threshold (MT) and applied over bilateral SMA. The target is located in the anterior-posterior direction over the transition between pre-SMA and SMA proper, (cortical point where a vertical line will pass through the anterior commissure). The center of a figure-of-eight coil will be placed over the target, guided with neuronavigation equipment that utilizes the anatomical brain image from the pre-cTBS scanning session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham continuous theta burst stimulation over the SMA
Description: The same stimulation parameters but a concealed sham coil will be used with only superficial magnetic stimulation to mimic the sensation of the active stimulation
Study: NCT01014325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergen extract
Description: sublingual application

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sublingual application
Study: NCT02426476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active heart rate variability biofeedback training
Description: resonant frequency breathing, attention focusing, positive emotional state

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham HRVB training
Description: passive relaxation
Study: NCT02023775

Intervention type: DEVICE
Intervention: Melody valve implantation
Study: NCT04018794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Behavioral/organizational skills intervention augmented with digital health application
Description: Behavioral/organizational skills intervention with digital health application augmentation
Study: NCT02691208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
Study: NCT00865397

Intervention type: DRUG
Intervention: insulin detemir
Description: Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
Study: NCT00725881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trans sodium crocetinate (TSC)
Description: Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% normal saline
Description: A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
Study: NCT00627653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: 148mg daily for 30 days
Study: NCT02308982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulins, Intravenous (Privigen)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04133792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 40mg
Description: 40 mg orally daily for 5 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 40 mg orally daily for 5 years.
Study: NCT04021836

Intervention type: OTHER
Group type: OTHER
Intervention: 3d evaluation of nasolabial change
Description: Evaluation of With vs without ala cinch suture after lefort 1 osteotomy

Intervention type: OTHER
Group type: OTHER
Intervention: 3d evaluation of nasolabial change
Description: Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
Study: NCT02499861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Genistein
Description: intravenous Decitabine with oral genistein
Study: NCT03127384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Lidocaine
Description: Hyaluronic acid based filler

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment control
Description: No-treatment control
Study: NCT00870402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: 25 mg per day for 9 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet per day for nine months
Study: NCT00277186

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Care Continuum
Description: Patient experience surgery through newly designed arthroplasty continuum

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: New Care Continuum
Description: Patient experience surgery through newly designed arthroplasty continuum
Study: NCT02171611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate pellets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate capsule
Study: NCT02124278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PUL-042 Inhalation Solution
Study: NCT03350295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifurtimox (Lampit, BAYA2502)
Description: Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
Study: NCT04143009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Friendship Bench
Description: EFB will include the following: integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions, and retention strategies to support engagement in care for HIV-infected women with PND. This intervention will include 4 individual prenatal and 2 group postnatal counseling sessions. To provide additional social support, one support session will be added, at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will conduct up to 6 home visits. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care (Control)
Description: Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Friendship Bench
Description: Adapted Friendship Bench (AFB): AFB will include the following: integrating problem solving therapy- based and antiretroviral therapy (ART) adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
Study: NCT03704142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound World Solutions CS50+
Description: Participants will be tested using the Sound World Solutions CS 50+ hearing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tweak Focus
Description: Participants will be tested using the Tweak Focus hearing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQ Earbuds
Description: Participants will be tested using the IQ Earbuds hearing devices.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bose Hearphones
Description: Participants will be tested using the Bose Hearphones hearing devices.
Study: NCT03268928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Story Starters Intervention
Description: Shared reading intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-list Control
Description: Wait-list control
Study: NCT04979689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive physical therapy
Description: Intensive physical therapy treatment protocol was given for 3 months 3 times a week including 1.5- 2-hour session. Pre and post treatment assessments were taken. It included stretching for 20 min, Proprioception on ball for 20 minutes, quadruped for 10 min, vibration therapy for 20 min, tapping twice a month for 5 days, sensory therapy with beans for 20 min, supine lying with hand below head for 10-15 min, texturing for 15 min and activity of making tower with cups and hitting in outward direction for 15-20 min.

Intervention type: OTHER
Group type: OTHER
Intervention: Non intensive physical therapy
Description: Non intensive therapy included 45 min session 3 times a week for 3 months. Pre and post treatment assessments were taken. The protocol included stretching for 20 min, cross friction massage for 15 min, Ball catch and throw for 15 min. progression was made from light to heavy weight ball.
Study: NCT01853995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixed Lingual Mandibular Growth Modificator (FLMGM)
Description: New Class II Corrector
Study: NCT01157754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel and ethynilestradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levonorgestrel and ethynilestradiol
Study: NCT02986503

Intervention type: DRUG
Intervention: Doxorubicin+cisplatin+ifosfamide
Description: Chemotherapy for Good responder high grade osteosarcoma

Intervention type: DRUG
Intervention: Doxorubicin+cisplatin+ifosfamide+methotrexate
Description: Chemotherapy for Poor responder high grade osteosarcoma
Study: NCT04247958

Intervention type: PROCEDURE
Intervention: Colorectal resection
Description: Robotic-assisted resection of the colon or rectum in subjects with benign or malignant colon or rectal disease, where SureForm™ Staplers are utilized for transection and/or creation of anastomosis.
Study: NCT03497585

Intervention type: BEHAVIORAL
Intervention: Activity pacing framework
Description: The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
Study: NCT01771055

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Galactose
Description: Galactose dripped into the abdomen after surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard surgical methods
Study: NCT00548015

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: state-of-the art strategy and extented strategy
Description: state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: state-of-the art strategy and extented strategy
Description: state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting